DDIT3 and diffuse large B-cell lymphoma: A prospective randomised trial in 399 elderly patients (aged 60–80 years) with previously untreated diffuse large B-cell lymphoma (DLCL) demonstrated a significant advantage for R-CHOP over CHOP alone (Coiffier et al, 2002).